Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 11, Pages 3919-3930Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI63888
Keywords
-
Categories
Funding
- Cancer Center Support Grant [P30 CA138313]
- COBRE in Lipidomics in Pathobiology [NIH P20RR017077]
- National Institute of Diabetes and Digestive and Kidney Diseases [F30DK092125]
- Department of Veterans Affairs
- NIH COBRE in Lipidomics and Pathobiology at MUSC
Ask authors/readers for more resources
Diabetic cardiomyopathy (DbCM), which consists of cardiac hypertrophy and failure in the absence of traditional risk factors, is a major contributor to increased heart failure risk in type 2 diabetes patients. In rodent models of DbCM, cardiac hypertrophy and dysfunction have been shown to depend upon saturated fatty acid (SFA) oversupply and de novo sphingolipid synthesis. However, it is not known whether these effects are mediated by bulk SFAs and sphingolipids or by individual lipid species. In this report, we demonstrate that a diet high in SFA induced cardiac hypertrophy, left ventricular systolic and diastolic dysfunction, and autophagy in mice. Furthermore, treatment with the SFA myristate, but not palmitate, induced hypertrophy and autophagy in adult primary cardiomyocytes. De novo sphingolipid synthesis was required for induction of all pathological features observed both in vitro and in vivo, and autophagy was required for induction of hypertrophy in vitro. Finally, we implicated a specific ceramide N-acyl chain length in this process and demonstrated a requirement for (dihydro)ceramide synthase 5 in cardiomyocyte autophagy and myristate-mediated hypertrophy. Thus, this report reveals a requirement for a specific sphingolipid metabolic route and dietary SFAs in the molecular pathogenesis of lipotoxic cardiomyopathy and hypertrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available